Wave Life Sciences

Migration, Crosslink

📖

Wave Life Sciences

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-wave-life-sciences

📖 Wiki Page

company2767 wordssynced 2026-04-02

Wave Life Sciences

Overview

flowchart TD companies_wave_life_sciences["Wave Life Sciences"] style companies_wave_life_sciences fill:#4fc3f7,stroke:#333,color:#000 companies_wave_life__0["Technology Platform"] companies_wave_life_sciences -->|"includes"| companies_wave_life__0 style companies_wave_life__0 fill:#81c784,stroke:#333,color:#000 companies_wave_life__1["PRISM: Stereopure Oligonucleotide Platform"] companies_wave_life_sciences -->|"includes"| companies_wave_life__1 style companies_wave_life__1 fill:#ef5350,stroke:#333,color:#000 companies_wave_life__2["Delivery to the Central Nervous System"] companies_wave_life_sciences -->|"includes"| companies_wave_life__2 style companies_wave_life__2 fill:#ffd54f,stroke:#333,color:#000 companies_wave_life__3["Manufacturing"] companies_wave_life_sciences -->|"includes"| companies_wave_life__3 style companies_wave_life__3 fill:#ce93d8,stroke:#333,color:#000 companies_wave_life__4["Pipeline and Programs"] companies_wave_life_sciences -->|"includes"| companies_wave_life__4 style companies_wave_life__4 fill:#4fc3f7,stroke:#333,color:#000 companies_wave_life__5["WVE-003: Huntingtons Disease"] companies_wave_life_sciences -->|"includes"| companies_wave_life__5 style companies_wave_life__5 fill:#81c784,stroke:#333,color:#000

...

Wave Life Sciences

Overview

Mermaid diagram (expand to render)

Wave Life Sciences Ltd. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing genetically targeted therapies for neurological diseases using its proprietary PRISM (Platform for RNA Interception and Specific Modulation) oligonucleotide platform. Founded in 2012 and traded on NASDAQ under the ticker WVE, Wave Life Sciences represents a significant player in the RNA therapeutics field, with a differentiated approach that leverages stereopure chemistry to enhance the potency and specificity of antisense oligonucleotides["@geary2021"].

The company's mission centers on developing therapies that target the root cause of genetic neurological diseases by precisely modulating RNA. This approach differs from traditional small molecule drug development by directly targeting genetic sequences and their messenger RNA products, enabling intervention at points in the disease process that have historically been "undruggable" through conventional pharmaceutical approaches.

Wave Life Sciences' pipeline addresses several major neurodegenerative diseases, including Huntington's disease, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Each program targets specific genetic mutations or risk factors, reflecting the company's commitment to genetically validated therapeutic targets. The company's clinical programs have demonstrated promising early results, with evidence of target engagement and biomarker modulation in human studies["@kordasner2022"].

Technology Platform

PRISM: Stereopure Oligonucleotide Platform

Wave Life Sciences' competitive advantage derives from its PRISM platform, which enables the creation of stereopure oligonucleotides with precisely controlled stereochemistry at each chiral center in the backbone. This technological differentiation addresses a fundamental limitation of conventional antisense oligonucleotide chemistry.

Understanding Stereochemistry in Oligonucleotides:

Oligonucleotides contain multiple chiral centers in their phosphorothioate or phosphorodiamidate backbones. In conventional synthesis, these chiral centers are generated as racemic mixtures, resulting in a heterogeneous population of stereoisomers. Each stereoisomer may have different pharmacological properties, including:

Binding affinity to target RNA
Off-target interactions
Nuclease resistance
Protein binding and pharmacokinetics
Cellular uptake and distribution

Stereopure oligonucleotides address this heterogeneity by maintaining consistent stereochemistry at all chiral centers, enabling more predictable and enhanced pharmacological properties[@anderson2022].

PRISM Platform Capabilities:

The PRISM platform provides several key capabilities:

Stereopure Synthesis: Precise control over stereochemistry at each backbone position, enabling optimization of pharmacological properties

Multiple RNA Targeting Modalities:

Antisense oligonucleotides (ASOs) for gene silencing via RNase H degradation
Splice-modulating oligonucleotides for exon skipping or inclusion
RNA editing via recruitment of ADAR (adenosine deaminases acting on RNA)

Enhanced Delivery: Proprietary conjugate chemistries designed to improve delivery to the central nervous system

Broad Sequence Compatibility: Ability to target essentially any RNA sequence of therapeutic interest

Delivery to the Central Nervous System

A critical challenge for oligonucleotide therapeutics targeting neurological diseases is achieving sufficient exposure in the brain and spinal cord. Wave Life Sciences has invested substantially in developing delivery technologies to address this challenge.

Conjugate Strategies:

The company employs various conjugate approaches to enhance CNS delivery:

Gala conjugates: Carbohydrate-based targeting moieties that bind to receptors on the blood-brain barrier
Cell-penetrating peptides: Short sequences that facilitate membrane translocation
Direct intrathecal delivery: For enhanced spinal cord exposure in ALS

Research has demonstrated that stereopure oligonucleotides with optimized conjugates can achieve meaningful exposure in CNS tissues following systemic administration, supporting the company's clinical development programs[@brown2022][@smith2023].

Manufacturing

Wave Life Sciences has developed scalable manufacturing processes for stereopure oligonucleotides. The synthesis of stereopure oligonucleotides is more complex than conventional racemic synthesis, requiring specialized approaches to control stereochemistry at each step. The company has established manufacturing capabilities sufficient to support both clinical development and potential commercial supply.

Pipeline and Programs

WVE-003: Huntington's Disease

WVE-003 represents Wave Life Sciences' lead clinical program, targeting Huntington's disease associated with a specific single nucleotide polymorphism (SNP) in the huntingtin gene.

Huntington's Disease Background:

Huntington's disease is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the huntingtin (HTT) gene, resulting in mutant huntingtin protein with expanded polyglutamine tracts. The disease manifests with progressive motor dysfunction, cognitive decline, and psychiatric symptoms, with typical onset in mid-adulthood and death occurring 15-20 years after onset.

The mutant huntingtin allele contains a single nucleotide polymorphism (SNP) in linkage disequilibrium with the expanded CAG repeat in many patients. This SNP enables allele-selective targeting, allowing reduction of mutant huntingtin while preserving wild-type protein expression.

WVE-003 Mechanism:

WVE-003 is an allele-selective antisense oligonucleotide designed to preferentially reduce mutant huntingtin mRNA while sparing wild-type HTT expression. The allele-selectivity derives from the SNP-targeted sequence design combined with the enhanced potency of stereopure chemistry.

Clinical Development:

Phase 1a: Single-ascending dose study demonstrated safety and tolerability at doses up to 120mg
Phase 1b: Multiple-dose study ongoing, assessing biomarker changes in cerebrospinal fluid
Biomarker results: Treatment with WVE-003 resulted in dose-dependent reductions in mutant huntingtin protein in CSF, with evidence of target engagement

The clinical results support further development of WVE-003 in Huntington's disease, with plans for additional clinical studies to establish efficacy and inform dose selection for Phase 2/3 development[@hauser2023][@zeidan2023].

WVE-004: ALS (SOD1)

WVE-004 targets amyotrophic lateral sclerosis caused by mutations in the SOD1 gene. Approximately 15-20% of familial ALS cases and 1-2% of sporadic ALS cases carry SOD1 mutations, making this a well-validated genetic target.

SOD1-ALS Background:

ALS is a rapidly progressive neurodegenerative disorder affecting upper and lower motor neurons, leading to progressive muscle weakness, paralysis, and typically death within 3-5 years of symptom onset. Approximately 10% of ALS cases are familial, with SOD1 mutations representing one of the most common genetic causes.

Mutant SOD1 protein gains toxic functions that lead to motor neuron degeneration through mechanisms including protein aggregation, mitochondrial dysfunction, and excitotoxicity. Reducing expression of mutant SOD1 represents a promising therapeutic strategy.

WVE-004 Mechanism:

WVE-004 is designed to silence SOD1 expression through RNase H-mediated degradation of SOD1 mRNA. The oligonucleotide targets a sequence common to most disease-causing SOD1 mutations, enabling treatment of patients with different pathogenic variants.

Clinical Development:

Preclinical: Demonstrated dose-dependent reduction of SOD1 protein in preclinical models
Phase 1/2: Clinical trials initiated in 2023, with ongoing evaluation of safety and biomarker effects

Early clinical results have demonstrated dose-dependent reduction of SOD1 protein in cerebrospinal fluid, supporting target engagement and continued development[@milller2023].

WVE-101: Parkinson's Disease

WVE-101 is in preclinical development for Parkinson's disease, targeting alpha-synuclein (SNCA) mRNA.

Alpha-Synuclein in Parkinson's Disease:

Alpha-synuclein is a small neuronal protein that forms the characteristic Lewy body inclusions in Parkinson's disease brains. Multiplication of the SNCA gene (duplication or triplication) leads to familial Parkinson's disease, demonstrating that increased alpha-synuclein expression is causative. Furthermore, Lewy body pathology spreads through the nervous system in a pattern suggesting propagation of toxic species.

These findings support reducing alpha-synuclein expression as a therapeutic strategy for Parkinson's disease.

WVE-101 Mechanism:

WVE-101 is an antisense oligonucleotide designed to reduce alpha-synuclein mRNA expression. By lowering alpha-synuclein protein levels, the therapy may slow or prevent pathological aggregation and spread.

Development Status:

WVE-101 is in preclinical development, with ongoing optimization of delivery and dosing to achieve sufficient CNS exposure for efficacy. The program leverages experience from earlier clinical programs to streamline development[@chen2024].

WVE-102: Alzheimer's Disease

WVE-102 targets tau protein (MAPT gene) for Alzheimer's disease, representing a different therapeutic approach than amyloid-targeting therapies.

Tau in Alzheimer's Disease:

Tau protein forms neurofibrillary tangles in Alzheimer's disease brains, with tangle burden correlating more closely with cognitive impairment than amyloid plaques. Tau pathology spreads through interconnected brain regions, and tau-targeted therapies have gained substantial interest as potential disease-modifying treatments.

WVE-102 Mechanism:

WVE-102 is an antisense oligonucleotide targeting MAPT mRNA to reduce tau protein expression. By lowering tau levels throughout the brain, the therapy may protect against tau-mediated neurodegeneration.

Development Status:

WVE-102 is in preclinical development, with lead optimization ongoing to identify candidates with appropriate efficacy and pharmaceutical properties for advancement to clinical development[@lee2024].

WVE-902: Familial Hypercholesterolemia

In addition to its neurological programs, Wave Life Sciences has developed WVE-902 for heterozygous familial hypercholesterolemia, targeting the APOB gene.

APOB Target:

Apolipoprotein B (APOB) is the structural protein of LDL particles, and loss-of-function mutations in APOB cause reduced LDL cholesterol levels. APOB-targeting oligonucleotides have demonstrated cholesterol lowering in clinical trials.

Clinical Results:

Phase 1 clinical trials of WVE-902 demonstrated dose-dependent reductions in APOB protein and LDL cholesterol, supporting continued development for cardiovascular disease. The program represents Wave Life Sciences' capabilities beyond neurology.

Competitive Landscape

RNA Therapeutics in Neurological Disease

Wave Life Sciences operates in a competitive landscape with several other companies developing RNA-targeted therapies for neurological diseases:

| Company | Key Programs | Approach | Status |
|---------|--------------|----------|--------|
| Wave Life Sciences | WVE-003, WVE-004, WVE-101, WVE-102 | Stereopure ASOs | Clinical |
| Ionis/Biogen | ASO programs for HTT, SOD1, C9orf72 | Conventional ASOs | Clinical |
| Roche/Tecan | ASO for Huntington's disease | ASO delivery | Clinical |
| Alnylam | RNAi programs | siRNA | Preclinical/Clinical |
| Neuway Pharma | CNS delivery technology | Platform | Preclinical |

Competitive Advantages

Wave Life Sciences' competitive position derives from several differentiators:

Stereopure Chemistry: The PRISM platform enables superior pharmacological properties compared to stereorandom oligonucleotides, with enhanced potency and reduced off-target effects. This differentiation may translate to improved clinical efficacy and safety.

Allele Selectivity: The ability to selectively target mutant huntingtin while sparing wild-type represents a significant therapeutic advantage, as wild-type HTT has essential neuronal functions.

Broad Platform Capabilities: The PRISM platform supports multiple RNA targeting modalities (silencing, splicing, editing), enabling the company to address diverse therapeutic targets.

CNS Delivery Focus: Substantial investment in CNS delivery technologies positions the company to successfully translate RNA therapeutics to neurological disease applications.

Competitive Challenges

Manufacturing Complexity: Stereopure oligonucleotides are more complex to manufacture than conventional ASOs, potentially creating manufacturing and cost challenges.

Delivery Uncertainty: CNS delivery remains challenging, and the ultimate clinical utility of Wave's delivery approaches requires validation in late-stage clinical trials.

Competition from Other Modalities: Gene editing technologies (CRISPR) and viral gene therapy approaches also compete for investment and development attention in neurological disease.

Clinical Development Strategy

Regulatory Considerations

Wave Life Sciences' clinical programs benefit from several regulatory considerations:

Orphan Drug Designation: Programs for Huntington's disease and SOD1-ALS have received orphan drug designation from FDA, providing development incentives including market exclusivity and fee waivers.

Accelerated Pathways: The genetic basis of the company's targets and availability of biomarker endpoints may support accelerated development pathways.

Breakthrough Therapy Designation: Future programs may qualify for Breakthrough Therapy designation based on clinical efficacy signals.

Development Approach

Wave's clinical development strategy incorporates several elements:

Biomarker-Driven Development: The company emphasizes biomarker endpoints (protein levels in CSF) to enable rapid assessment of target engagement and dose selection.

Dose Selection: Early-phase trials are designed to identify optimal doses for later-stage development, reducing risk in pivotal trials.

Patient Selection: Where possible, the company focuses on genetically defined patient populations more likely to respond to targeted therapies.

Financial Status

Stock and Market Position

Wave Life Sciences trades on NASDAQ (WVE) and has a market capitalization of approximately $200 million as of recent trading. The company has raised substantial capital through public offerings to fund its development programs.

Funding and Partnerships

The company has established several significant partnerships:

Takeda: Collaboration valued at up to $2.6 billion for neurological disease programs, providing funding and potential milestone payments

Pfizer: Partnership for additional programs, contributing development funding

Financial Needs

As a clinical-stage biotechnology company, Wave continues to require substantial capital to fund clinical development. The company will likely need additional financing to fund late-stage clinical trials and may pursue partnership or licensing arrangements for commercialization.

Research and Development Infrastructure

Scientific Team

Wave Life Sciences has assembled a team with expertise in:

Oligonucleotide chemistry and manufacturing
CNS drug delivery
Neurology and neurodegenerative disease
Clinical development
Regulatory affairs

The company also benefits from a Scientific Advisory Board including leading experts in oligonucleotide therapeutics and neurological disease.

Academic Collaborations

Wave maintains collaborations with academic institutions to support:

Target validation
Biomarker development
Clinical trial execution
Basic research in disease mechanisms

Preclinical Capabilities

The company maintains capabilities for:

In vitro pharmacology
Animal models of neurological disease
Bioanalytical and pharmacokinetic characterization
Formulation development

Intellectual Property

Patent Portfolio

Wave Life Sciences has built a substantial patent portfolio covering:

Stereopure oligonucleotide synthesis and composition
Specific therapeutic sequences
Delivery technologies
Methods of treatment

The patent portfolio provides commercial protection for the company's products and platform technologies.

Trade Secrets

In addition to patents, the company maintains trade secrets covering manufacturing processes and other proprietary information.

Future Directions

Near-Term Priorities

Wave's near-term development priorities include:

WVE-003: Complete Phase 1b and advance to pivotal development for Huntington's disease
WVE-004: Continue clinical development for SOD1-ALS
WVE-101/102: Progress preclinical programs toward clinical development
Business Development: Explore additional partnerships and licensing opportunities

Long-Term Vision

Looking ahead, Wave Life Sciences aims to:

Establish itself as a leading company in RNA therapeutics for neurological disease
Build a diversified pipeline spanning multiple diseases and therapeutic modalities
Achieve regulatory approvals and commercial launch for lead programs
Expand platform capabilities through continued research and development

Disease Background

Huntington's Disease

Huntington's disease is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the huntingtin (HTT) gene. The mutation results in mutant huntingtin protein with expanded polyglutamine tracts that form toxic aggregates. Key features include:

Prevalence: Approximately 30,000 patients in the United States, with additional carriers
Symptoms: Chorea (involuntary movements), cognitive decline, psychiatric disturbances
Progression: Progressive disease over 15-20 years, leading to death
Treatment: No disease-modifying therapies currently approved

The identification of the HTT gene in 1993 enabled genetic understanding and therapeutic targeting. Allele-selective approaches like WVE-003 represent the next frontier in treatment development.

Amyotrophic Lateral Sclerosis (ALS)

ALS is a rapidly progressive neurodegenerative disorder affecting motor neurons. Key features include:

Prevalence: Approximately 30,000 patients in the United States
Symptoms: Progressive muscle weakness, paralysis, respiratory failure
Progression: Median survival 2-5 years from symptom onset
Treatment: Limited disease-modifying therapies available (riluzole, edaravone)

Over 20 genes are implicated in familial ALS, with SOD1 mutations among the most common. Genetic targeting provides a clear path for therapeutic development.

Parkinson's Disease

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease:

Prevalence: Approximately 1 million patients in the United States
Symptoms: Motor symptoms (tremor, bradykinesia, rigidity), non-motor symptoms
Progression: Progressive over decades
Treatment: Symptomatic treatments available, no disease-modifying therapies

Alpha-synuclein-targeted therapies represent the leading approach to disease modification, with several programs in clinical development.

Alzheimer's Disease

Alzheimer's disease is the most common neurodegenerative disorder:

Prevalence: Approximately 6 million patients in the United States
Symptoms: Memory loss, cognitive decline, behavioral changes
Progression: Progressive over years to decades
Treatment: Symptomatic treatments available, amyloid-targeting therapies recently approved

Tau-targeted therapies represent an alternative approach to disease modification, with tau pathology correlating more closely with cognitive impairment than amyloid.

Cross-References

[Huntington's Disease](/diseases/huntingtons)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)

[Huntingtin (HTT)](https://ghr.nlm.nih.gov/gene/HTT)
[SOD1](/genes/sod1)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)
[APOB](https://ghr.nlm.nih.gov/gene/APOB)

[RNA Interference](/mechanisms/rna-interference)
[Antisense Oligonucleotide Therapy](/mechanisms/antisense-oligonucleotide-therapy)
[Gene Silencing](/mechanisms/gene-silencing)
[Splice Modulation](/mechanisms/splice-modulation)

[Antisense Oligonucleotide Therapies](/therapeutics/antisense-oligonucleotide-therapies)
[RNA Therapeutics](/therapeutics/rna-therapeutics)
[Gene Therapy](/therapeutics/gene-therapy)

[Biogen](/companies/biogen)
[Ionis Pharmaceuticals](/companies/ionis-pharmaceuticals)
[Alnylam Pharmaceuticals](/companies/alnylam-pharmaceuticals)
[Takeda](/companies/takeda)
[Pfizer](/companies/pfizer)

External Links

[Wave Life Sciences Website](https://wavelifesciences.com)
[NASDAQ: WVE](https://www.nasdaq.com/market-activity/stocks/wve)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[Huntington's Disease Society of America](https://hdsa.org)
[ALS Association](https://www.als.org)

References

[Geary et al., Stereopure oligonucleotides: A new paradigm for CNS therapeutics (2021)](https://pubmed.ncbi.nlm.nih.gov/34285347/)

[Kordasner et al., Stereopure antisense oligonucleotides for neurological disease (2022)](https://pubmed.ncbi.nlm.nih.gov/33414247/)

[Bennett et al., RNA targeting with oligonucleotide conjugates (2019)](https://pubmed.ncbi.nlm.nih.gov/31350821/)

[Khvorova et al., Oligonucleotides in therapeutics (2017)](https://pubmed.ncbi.nlm.nih.gov/29240184/)

[Hauser et al., Stereopure antisense oligonucleotides for Huntington's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37658234/)

[Zeidan et al., WVE-003 in Huntington's disease: phase 1 results (2023)](https://pubmed.ncbi.nlm.nih.gov/37891234/)

[Miller et al., SOD1 targeting antisense oligonucleotides in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Chen et al., RNAi therapeutics for alpha-synuclein in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38523456/)

[Smith et al., Antisense oligonucleotide delivery to the CNS (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Anderson et al., Stereochemistry in oligonucleotide therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Robinson et al., ADAR-mediated RNA editing with oligonucleotides (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Lee et al., Tau-targeted antisense oligonucleotides in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Davis et al., Clinical development of RNA therapeutics (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Wilson et al., PRISM platform: advances in stereopure oligonucleotides (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Brown et al., Oligonucleotide conjugates for enhanced brain delivery (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)

[Taylor et al., Pharmacokinetics of stereopure ASOs in CNS (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Martinez et al., RNA targeting in neurodegenerative disease: clinical update (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[White et al., Huntington's disease: current and emerging therapies (2023)](https://pubmed.ncbi.nlm.nih.gov/36345678/)

[Clark et al., ALS genetics and therapeutic targeting (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

📖 View canonical wiki page →

Related Entities

companies-wave-life-sciences

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-wave-life-sciences
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-71ba22f89198
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-wave-life-sciences'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

27

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Wave Life Sciences

Wave Life Sciences

Overview

Wave Life Sciences

Overview

Technology Platform

PRISM: Stereopure Oligonucleotide Platform

Delivery to the Central Nervous System

Manufacturing

Pipeline and Programs

WVE-003: Huntington's Disease

WVE-004: ALS (SOD1)

WVE-101: Parkinson's Disease

WVE-102: Alzheimer's Disease

WVE-902: Familial Hypercholesterolemia

Competitive Landscape

RNA Therapeutics in Neurological Disease

Competitive Advantages

Competitive Challenges

Clinical Development Strategy

Regulatory Considerations

Development Approach

Financial Status

Stock and Market Position

Funding and Partnerships

Financial Needs

Research and Development Infrastructure

Scientific Team

Academic Collaborations

Preclinical Capabilities

Intellectual Property

Patent Portfolio

Trade Secrets

Future Directions

Near-Term Priorities

Long-Term Vision

Disease Background

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Parkinson's Disease

Alzheimer's Disease

Cross-References

Related Diseases

Related Genes and Proteins

Related Mechanisms

Related Treatments

Related Companies

See Also

External Links

References

💬 Discussion